1476 related articles for article (PubMed ID: 15753383)
21. Interaction of IGF signaling and the androgen receptor in prostate cancer progression.
Wu JD; Haugk K; Woodke L; Nelson P; Coleman I; Plymate SR
J Cell Biochem; 2006 Oct; 99(2):392-401. PubMed ID: 16639715
[TBL] [Abstract][Full Text] [Related]
22. Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells.
Segal CV; Koufaris C; Powell C; Gooderham NJ
Toxicology; 2015 Jul; 333():45-52. PubMed ID: 25846647
[TBL] [Abstract][Full Text] [Related]
23. Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells.
Wu Z; Conaway M; Gioeli D; Weber MJ; Theodorescu D
Prostate; 2006 Jul; 66(10):1114-23. PubMed ID: 16637073
[TBL] [Abstract][Full Text] [Related]
24. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
25. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
Swinnen JV; Esquenet M; Goossens K; Heyns W; Verhoeven G
Cancer Res; 1997 Mar; 57(6):1086-90. PubMed ID: 9067276
[TBL] [Abstract][Full Text] [Related]
26. The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer.
Comuzzi B; Nemes C; Schmidt S; Jasarevic Z; Lodde M; Pycha A; Bartsch G; Offner F; Culig Z; Hobisch A
J Pathol; 2004 Oct; 204(2):159-66. PubMed ID: 15378487
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway.
Miyake H; Nelson C; Rennie PS; Gleave ME
Endocrinology; 2000 Jun; 141(6):2257-65. PubMed ID: 10830316
[TBL] [Abstract][Full Text] [Related]
28. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
29. Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling.
Malaguarnera R; Sacco A; Morcavallo A; Squatrito S; Migliaccio A; Morrione A; Maggiolini M; Belfiore A
Endocrinology; 2014 Apr; 155(4):1207-21. PubMed ID: 24437490
[TBL] [Abstract][Full Text] [Related]
30. Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.
Chen F; Knecht K; Leu C; Rutledge SJ; Scafonas A; Gambone C; Vogel R; Zhang H; Kasparcova V; Bai C; Harada S; Schmidt A; Reszka A; Freedman L
J Steroid Biochem Mol Biol; 2004 Aug; 91(4-5):247-57. PubMed ID: 15336702
[TBL] [Abstract][Full Text] [Related]
31. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C
Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626
[TBL] [Abstract][Full Text] [Related]
32. Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the alphavbeta3 integrin and PI3-K/Akt signaling.
Montagnani Marelli M; Moretti RM; Procacci P; Motta M; Limonta P
Int J Oncol; 2006 Mar; 28(3):723-30. PubMed ID: 16465378
[TBL] [Abstract][Full Text] [Related]
33. Inter-related in vitro effects of androgens, fatty acids and oxidative stress in prostate cancer: a mechanistic model supporting prevention strategies.
Lin H; Lu JP; Laflamme P; Qiao S; Shayegan B; Bryskin I; Monardo L; Wilson BC; Singh G; Pinthus JH
Int J Oncol; 2010 Oct; 37(4):761-6. PubMed ID: 20811696
[TBL] [Abstract][Full Text] [Related]
34. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
Zhao XY; Peehl DM; Navone NM; Feldman D
Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
[TBL] [Abstract][Full Text] [Related]
35. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells.
Church DR; Lee E; Thompson TA; Basu HS; Ripple MO; Ariazi EA; Wilding G
Prostate; 2005 May; 63(2):155-68. PubMed ID: 15486991
[TBL] [Abstract][Full Text] [Related]
36. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells.
Shigemura K; Sung SY; Kubo H; Arnold RS; Fujisawa M; Gotoh A; Zhau HE; Chung LW
Prostate; 2007 May; 67(7):722-31. PubMed ID: 17342749
[TBL] [Abstract][Full Text] [Related]
37. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells.
Mabjeesh NJ; Willard MT; Frederickson CE; Zhong H; Simons JW
Clin Cancer Res; 2003 Jul; 9(7):2416-25. PubMed ID: 12855613
[TBL] [Abstract][Full Text] [Related]
38. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
Wang LG; Liu XM; Kreis W; Budman DR
Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
[TBL] [Abstract][Full Text] [Related]
39. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of apoptosis in prostate cancer cells by androgens is mediated through downregulation of c-Jun N-terminal kinase activation.
Lorenzo PI; Saatcioglu F
Neoplasia; 2008 May; 10(5):418-28. PubMed ID: 18472959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
